| Mar 16, 2026 | Unnatural Products | $45.0M Series B | Nicholas Shekerdemian | argenx, First Spark Ventures, Merck |
| Dec 1, 2025 | Protego Biopharma | $130.0M Series B | Tim Lohoff, Novartis | Digitalis Ventures, Lightspeed Venture Partners, MPM Capital, Omega Funds, Scripps Research, Christopher Weyrer, MD, PhD, YK Bioventures |
| Jun 1, 2025 | Actio Biosciences | $66.0M Series B | Deerfield Management, Regeneron Ventures | Canaan Partners, Canaan Partners, Euclidean Capital |
| Mar 1, 2025 | Hillstar Bio | $67.0M Series A | Matthias Van Woensel, Lauren Mifflin, Hummingbird Bioscience, Novo Holdings | Frazier Healthcare Partners, Norwest Venture Partners, Omega Funds |
| Jan 1, 2025 | Alesta Therapeutics | $67.0M Series A | Janwillem Naesens, Frazier Life Sciences | Frazier Healthcare Partners, Novartis Venture Fund, Sanofi Ventures, Shinichiro Fuse |
| Jan 1, 2024 | Accent Therapeutics | $75.0M Series C | — | Atlas Venture, F-Prime Capital Partners, Leaps by Bayer, Nextech Invest, The Column Group, AbbVie Ventures, Bristol Myers Squibb, EcoR1 Capital, Google Ventures, Johnson & Johnson Innovation, Naveen Krishnan, Mirae Asset Venture Investment, The Mark Foundation for Cancer Research, Timefolio Capital |
| Sep 1, 2023 | Actio Biosciences | $55.0M Series A | Nina Kjellson, George Golumbeski | Canaan Partners, Deerfield Management, Alex Tkachenko, Euclidean Capital |
| Mar 1, 2023 | QurAlis | $88.0M Series B | Sanofi Ventures, Droia Ventures, Cillian King | 15th Rock Ventures, Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, Brandon Capital Partners, EQT Life Sciences, Scott Biller, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Northpond Ventures, Polaris Partners, ALS Investment Fund, Amgen Ventures, Dementia Discovery Fund, Dolby Family Ventures, LS Polaris Innovation Fund, Mission Bay Capital, Mitsui & Co. Global Investment, MP Healthcare Venture Management, Sanford Biosciences |
| Mar 1, 2023 | Volastra Therapeutics | $60.0M Series A | ARCH Venture Partners, Eli Lilly and Company, Polaris Partners | NanoDimension, Catalio Capital Management, Cornell University, Meyer Ventures, Vida Ventures |
| Jul 1, 2022 | Vicinitas Therapeutics | $65.0M Series A | Deerfield Management, Jorge Conde | 5AM Ventures, Andreessen Horowitz, Maverick Capital, Northpond Ventures, Vivo Capital, Berkeley Catalyst Fund, George Golumbeski, Google Ventures, The Mark Foundation for Cancer Research |
| Jan 1, 2022 | AmbAgon Therapeutics | $85.0M Series A | Melissa McCracken, PhD | Nextech Invest, AbbVie Ventures, INKEF Capital, Mission BioCapital, MRL Ventures Fund, Adam Rosenberg, Surveyor Capital |
| Jul 9, 2021 | Muna Therapeutics | $73.0M Series A | Droia Ventures, LSP, Morten Graugaard Døssing, Sofinnova Partners | LS Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures, VIB |
| May 1, 2021 | Hummingbird Bioscience | $130.0M Series C | Ken Harrison | Frazier Healthcare Partners, Affinity Asset Advisors, Ally Bridge Group, Altrium Capital Management, Amgen Ventures, EDBI, Heritas Capital, Mirae Asset, Morningside Ventures, Octagon Capital, Polaris Partners, Pureos Bioventures, Kiel Kim |
| Apr 1, 2021 | Volastra Therapeutics | $32.0M Seed | — | NanoDimension, Polaris Partners, ARCH Venture Partners, Catalio Capital Management, Amy Schulman, Quark Venture, Vida Ventures |
| Feb 1, 2021 | Cyteir Therapeutics | $80.0M Series C | Derek DiRocco | Advanced Technology Ventures, Aisling Capital, Dolby Family Ventures, Novo Ventures, RA Capital, Venrock, Acuta Capital Partners, Ally Bridge Group, Ample Plus Fund, Avidity Partners, CaaS Capital Management, Janus Henderson Investors, Lightstone Ventures, Osage University Partners |
| May 1, 2020 | QurAlis | $42.0M Series A | INKEF Capital, Mission BioCapital, Jonathan Behr, Luc Dochez, Amy Schulman | Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, EQT Life Sciences, Polaris Partners, Amgen Ventures, Dolby Family Ventures, Mitsui & Co. Global Investment, MP Healthcare Venture Management, Sanford Biosciences |
| Apr 1, 2020 | Accent Therapeutics | $63.0M Series B | Oleg Nodelman | Atlas Venture, F-Prime Capital Partners, Nextech Invest, The Column Group, AbbVie Ventures, Google Ventures, NS Investment, The Mark Foundation for Cancer Research |
| Feb 1, 2020 | Volastra Therapeutics | $12.0M Seed | Amy Schulman | NanoDimension, Polaris Partners, ARCH Venture Partners, Luc Dochez, Zafrira Avnur |
| Oct 1, 2019 | Cyteir Therapeutics | $40.0M Series B | Novo Ventures | Advanced Technology Ventures, Aisling Capital, RA Capital, Venrock, Celgene, Lightstone Ventures, Osage University Partners |
| Mar 1, 2018 | Cyteir Therapeutics | $29.0M Series B | Venrock | Advanced Technology Ventures, Novo Ventures, RA Capital, Maria Palmisano, Bart Van Hooland, Jean George |
| Nov 13, 2017 | Arcus Biosciences | $107.0M Series C | Google Ventures | Aisling Capital, BVF Partners, Celgene, Decheng Capital, EcoR1 Capital, Foresite Capital, Hillhouse Capital Group, Invus Opportunities, Leerink Partners, Taiho Ventures, The Column Group, Wellington Management |
| Sep 1, 2016 | Arcus Biosciences | $70.0M Series B | — | Celgene, Foresite Capital, Google Ventures, Invus, Novartis, Stanford University, Taiho Ventures, The Column Group |
